KLK3 and cancer: Considering the disparities in PC between races and the potential for referral to an oncologist for cancer management that may bias estimates of outcome rates, we assessed PSA testing frequency during follow-up, enzalutamide treatment duration, and duration of follow-up but found no meaningful difference by race (Supplementary Fig. 1).